tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2017-2-83-89tumors-347Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISПрименение метформина – целевая метаболическая терапия в онкологииMetformin as target metabolic drug in oncologyШатоваО. П.ShatovaO. P.

к.м.н., заведующая кафедрой биологической химии

MD, PhD, Head of the Biological Chemistry Department

shatova.op@gmail.comКаплунД. С.KaplunD. S.

аспирант кафедры биологической химии

Postgraduate at the Biological Chemistry Department

kaplun.dascha@gmail.comЗинковичИ. И.ZinkovychI. I.

д.м.н., первый проректор, профессор кафедры биологической химии

MD, PhD, DSc, Professor at the Biological Chemistry Department

zii@dnmu.ru«Донецкий национальный медицинский университет им. М. Горького» (ДонНМУ), ДонецкУкраинаM. Gorky Donetsk National Medical University, DonetskUkraine201720072017028389Copyright © Шатова О.П., Каплун Д.С., Зинкович И.И., 20172017Шатова О.П., Каплун Д.С., Зинкович И.И.Shatova O.P., Kaplun D.S., Zinkovych I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/347

Общеизвестно широкое применение метформина для лечения сахарного диабета II типа. Однако в многочисленных эпидемиологических исследованиях было показано, что больные, принимавшие метформин, реже болели раком различной локализации и имели лучший прогноз по выживаемости. Многие исследователи считают метформин таргетным метаболическим препаратом, который имеет множество целей: действует на митохондрии, влияет на внутриклеточный сигналинг, блокирует каналы, тормозит образование эндотелиального и тромбоцитарного факторов роста, снижает уровень витаминов, вовлеченных в синтез нуклеотидов и аминокислот и пр. Также установлено, что метформин относится к группе «метабостемных» препаратов, то есть действует на раковые стволовые клетки, блокируя их деление. Нами проведено обзорное исследование, которое освещает важнейшие механизмы и области применения метформина. Изучение применения данного препарата в онкологии позволит понять патогенетические мишени метаболической терапии и профилактики онкопатологий. 

It is well known that metformin is widely used for the treatment of type II diabetes mellitus. However, in numerous epidemiological studies it was shown that patients taking metformin were less likely to have cancer of different localization and had better survival prognosis. Many researchers consider metformin to be a targeted metabolic drug that has many goals: it acts on mitochondria, affects intracellular signaling, blocks channels, inhibits the formation of endothelial and platelet growth factors, reduces the level of vitamins involved in the synthesis of nucleotides and amino acids, etc. It has also been established that metformin belongs to the group of “metabostemness” drugs, that is, it acts on cancer stem cells, blocking their division. We conducted a survey study that highlights the most important mechanisms and fields of application of metformin. The study of the use of this drug in oncology will make it possible to understand the pathogenetic targets of metabolic therapy and the prevention of cancer. 

метформинракметилированиефосфолипидыраковые стволовые клеткиMAP-киназагликолизвитамин В12metformincancermethylationphospholipidscancer stem cellsMAP-kinaseglycolysisvitamin В12ReferencesYu T., Wang C., Yang J., Guo Y., Wu Y., Li X. Metformin inhibits SUV39H1-mediated migration of prostate cancer cells, Oncogenesis, 2017, Vol. 6, No. 5, p. e324.Yu T., Wang C., Yang J., Guo Y., Wu Y., Li X. Metformin inhibits SUV39H1-mediated migration of prostate cancer cells, Oncogenesis, 2017, Vol. 6, No. 5, p. e324.Cho Y.H., Ko B.M., Kim S.H., Myung Y.S., Choi J.H., Han J.P. et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest. Res., 2014, Vol. 12, No. 2, pp. 139–145.Cho Y.H., Ko B.M., Kim S.H., Myung Y.S., Choi J.H., Han J.P. et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest. Res., 2014, Vol. 12, No. 2, pp. 139–145.Hense H.W., Geier A.S. Re: “reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and metaanalysis”, Am. J. Epidemiol., 2014, Vol. 180, No. 11, pp. 1130–1131.Hense H.W., Geier A.S. Re: “reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and metaanalysis”, Am. J. Epidemiol., 2014, Vol. 180, No. 11, pp. 1130–1131.Schuler K.M., Rambally B.S., DiFurio M. J., Sampey B.P., Gehrig P.A., Makowski L. et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer, Cancer Med., 2015, Vol. 4, No. 2, pp. 161–173.Schuler K.M., Rambally B.S., DiFurio M. J., Sampey B.P., Gehrig P.A., Makowski L. et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer, Cancer Med., 2015, Vol. 4, No. 2, pp. 161–173.Gong J., Robbins L.A., Lugea A., Waldron R. T., Jeon C.Y., Pandol S. J. Diabetes, pancreatic cancer, and metformin therapy, Front. Physiol., 2014, Vol. 5, p. 426.Gong J., Robbins L.A., Lugea A., Waldron R. T., Jeon C.Y., Pandol S. J. Diabetes, pancreatic cancer, and metformin therapy, Front. Physiol., 2014, Vol. 5, p. 426.Gritti M., Wurth R., Angelini M., Barbieri F., Peretti M., Pizzi E. et al. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current, Oncotarget, 2014, Vol. 5, No. 22, pp. 11252–11268.Gritti M., Wurth R., Angelini M., Barbieri F., Peretti M., Pizzi E. et al. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current, Oncotarget, 2014, Vol. 5, No. 22, pp. 11252–11268.Daugan M., Dufay W.A., d’Hayer B., Boudy V. Metformin: An anti-diabetic drug to fight cancer, Pharmacol. Res., 2016, Vol. 113 (Pt. A), pp. 675–685.Daugan M., Dufay W.A., d’Hayer B., Boudy V. Metformin: An anti-diabetic drug to fight cancer, Pharmacol. Res., 2016, Vol. 113 (Pt. A), pp. 675–685.Falah R.R., Talib W.H., Shbailat S. J. Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis, Ther. Adv. Med. Oncol., 2017, Vol. 9, No. 4, pp. 235–252.Falah R.R., Talib W.H., Shbailat S. J. Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis, Ther. Adv. Med. Oncol., 2017, Vol. 9, No. 4, pp. 235–252.Abo-Elmatty D.M., Ahmed E.A., Tawfik M.K., Helmy S.A. Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors, Int. Immunopharmacol., 2017, Vol. 44, pp. 72–86.Abo-Elmatty D.M., Ahmed E.A., Tawfik M.K., Helmy S.A. Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors, Int. Immunopharmacol., 2017, Vol. 44, pp. 72–86.Shatova O.P., Butenko E.V., Khomutov E.V., Kaplun D.S., Sedakov I. E., Zinkovych I. I. Metformin impact on purine metabolism in breast cancer, Biomed. Khim., 2016, Vol. 62, No. 3, pp. 302–305.Shatova O.P., Butenko E.V., Khomutov E.V., Kaplun D.S., Sedakov I. E., Zinkovych I. I. Metformin impact on purine metabolism in breast cancer, Biomed. Khim., 2016, Vol. 62, No. 3, pp. 302–305.Janzer A., German N. J., Gonzalez-Herrera K.N., Asara J.M., Haigis M.C., Struhl K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells, Proc. Natl. Acad. Sci., USA, 2014, Vol. 111, No. 29, pp. 10574–10579.Janzer A., German N. J., Gonzalez-Herrera K.N., Asara J.M., Haigis M.C., Struhl K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells, Proc. Natl. Acad. Sci., USA, 2014, Vol. 111, No. 29, pp. 10574–10579.Fuentes-Mattei E., Velazquez-Torres G., Phan L., Zhang F., Chou P.C., Shin J.H. et al. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer, J. Natl. Cancer Inst., 2014, Vol. 106, No. 7.Fuentes-Mattei E., Velazquez-Torres G., Phan L., Zhang F., Chou P.C., Shin J.H. et al. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer, J. Natl. Cancer Inst., 2014, Vol. 106, No. 7.Kolb R., Phan L., Borcherding N., Liu Y., Yuan F., Janowski A.M. et al. Obesity-associated NLRC4 inflammasome activation drives breast cancer progression, Nat. Commun., 2016, Vol. 7: 13007.Kolb R., Phan L., Borcherding N., Liu Y., Yuan F., Janowski A.M. et al. Obesity-associated NLRC4 inflammasome activation drives breast cancer progression, Nat. Commun., 2016, Vol. 7: 13007.Menendez J.A., Joven J. Energy metabolism and metabolic sensors in stem cells: the metabostem crossroads of aging and cancer, Adv. Exp. Med. Biol., 2014, No. 824, pp. 117–140.Menendez J.A., Joven J. Energy metabolism and metabolic sensors in stem cells: the metabostem crossroads of aging and cancer, Adv. Exp. Med. Biol., 2014, No. 824, pp. 117–140.Kourelis T.V., Siegel R.D. Metformin and cancer: new applications for an old drug, Med. Oncol., 2012, Vol. 29, No. 2, pp. 1314–1327.Kourelis T.V., Siegel R.D. Metformin and cancer: new applications for an old drug, Med. Oncol., 2012, Vol. 29, No. 2, pp. 1314–1327.Damjanovic A., Matic I.Z., Ethordic M., Ethurovic M.N., Nikolic S., Roki K. et al. Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells, Pathol. Oncol. Res., 2015, Vol. 21, No. 3, pp. 605–612.Damjanovic A., Matic I.Z., Ethordic M., Ethurovic M.N., Nikolic S., Roki K. et al. Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells, Pathol. Oncol. Res., 2015, Vol. 21, No. 3, pp. 605–612.Snima K.S., Pillai P., Cherian A.M., Nair S.V., Lakshmanan V.K. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy, Curr. Cancer Drug Targets, 2014, Vol. 14, No. 8, pp. 727–736.Snima K.S., Pillai P., Cherian A.M., Nair S.V., Lakshmanan V.K. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy, Curr. Cancer Drug Targets, 2014, Vol. 14, No. 8, pp. 727–736.Pulito C., Donzelli S., Muti P., Puzzo L., Strano S., Blandino G. MicroRNAs and cancer metabolism reprogramming: the paradigm of metformin, Ann. Transl. Med., 2014, Vol. 2, No. 6, p. 58.Pulito C., Donzelli S., Muti P., Puzzo L., Strano S., Blandino G. MicroRNAs and cancer metabolism reprogramming: the paradigm of metformin, Ann. Transl. Med., 2014, Vol. 2, No. 6, p. 58.Snima K.S., Jayakumar R., Unnikrishnan A.G., Nair S.V., Lakshmanan V.K. O-carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells, Carbohydr. Polym., 2012, Vol. 89, No. 3, pp. 1003–1007.Snima K.S., Jayakumar R., Unnikrishnan A.G., Nair S.V., Lakshmanan V.K. O-carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells, Carbohydr. Polym., 2012, Vol. 89, No. 3, pp. 1003–1007.Wurth R., Barbieri F., Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells, Biomed. Res. Int., 2014, Vol. 2014, 126586.Wurth R., Barbieri F., Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells, Biomed. Res. Int., 2014, Vol. 2014, 126586.Zhao D., Long X. D., Lu T. F., Wang T., Zhang W. W., Liu Y. X. et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma, Int. J. Cancer, 2015, Vol. 136, No. 11, pp. 2556–2565.Zhao D., Long X. D., Lu T. F., Wang T., Zhang W. W., Liu Y. X. et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma, Int. J. Cancer, 2015, Vol. 136, No. 11, pp. 2556–2565.Zhang J., Shen C., Wang L., Ma Q., Xia P., Qi M. et al. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4, Biochem. Biophys. Res. Commun., 2014, Vol. 452, No. 3, pp. 746–752.Zhang J., Shen C., Wang L., Ma Q., Xia P., Qi M. et al. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4, Biochem. Biophys. Res. Commun., 2014, Vol. 452, No. 3, pp. 746–752.Bao B., Azmi A. S., Ali S., Zaiem F., Sarkar F.H. Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers, Ann. Transl. Med., 2014, Vol. 2, No. 6, p. 59.Bao B., Azmi A. S., Ali S., Zaiem F., Sarkar F.H. Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers, Ann. Transl. Med., 2014, Vol. 2, No. 6, p. 59.Zhong T., Men Y., Lu L., Geng T., Zhou J., Mitsuhashi A. et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis, Oncogene, 2017, Vol. 36, No. 17, pp. 2345–2354.Zhong T., Men Y., Lu L., Geng T., Zhou J., Mitsuhashi A. et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis, Oncogene, 2017, Vol. 36, No. 17, pp. 2345–2354.Uehara T., Mitsuhashi A., Tsuruoka N., Shozu M. Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro, Oncol. Rep., 2015, Vol. 33, No. 2, pp. 744–750.Uehara T., Mitsuhashi A., Tsuruoka N., Shozu M. Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro, Oncol. Rep., 2015, Vol. 33, No. 2, pp. 744–750.Baranov V.S., Glotov O.S., Baranova E.V. Genetic and epigenetic news in gerontology, Adv. Gerontol., 2014, Vol. 27, No. 2, pp. 247–256.Baranov V.S., Glotov O.S., Baranova E.V. Genetic and epigenetic news in gerontology, Adv. Gerontol., 2014, Vol. 27, No. 2, pp. 247–256.Liu C., Zeng X., Li Y., Ma H., Song J., Li Y. et al. Investigation of hypoglycemic, hypolipidemic and antinephritic activities of Paecilomyces tenuipesN45 in diet/streptozotocininduced diabetic rats, Mol. Med. Rep., 2017, Vol. 15, No. 5, pp. 2807–2813.Liu C., Zeng X., Li Y., Ma H., Song J., Li Y. et al. Investigation of hypoglycemic, hypolipidemic and antinephritic activities of Paecilomyces tenuipesN45 in diet/streptozotocininduced diabetic rats, Mol. Med. Rep., 2017, Vol. 15, No. 5, pp. 2807–2813.Smith T.A., Phyu S.M. Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells, PLoS One, 2016, Vol. 11, No. 3, e0151179.Smith T.A., Phyu S.M. Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells, PLoS One, 2016, Vol. 11, No. 3, e0151179.Huang Y., Fu J. F., Shi H.B., Liu L.R. Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/ lysophosphatidylcholine lipoapoptosis pathway in hepatocytes, Zhonghua Er Ke Za Zhi, 2011, Vol. 49, No. 2, pp. 139–145.Huang Y., Fu J. F., Shi H.B., Liu L.R. Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/ lysophosphatidylcholine lipoapoptosis pathway in hepatocytes, Zhonghua Er Ke Za Zhi, 2011, Vol. 49, No. 2, pp. 139–145.Luengo A., Sullivan L.B., Heiden M.G. Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy, BMC Biol., 2014, Vol. 12, p. 82.Luengo A., Sullivan L.B., Heiden M.G. Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy, BMC Biol., 2014, Vol. 12, p. 82.Son H. J., Lee J., Lee S.Y., Kim E.K., Park M. J., Kim K.W. et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis, Mediators Inflamm., 2014, Vol. 2014, p. 973986.Son H. J., Lee J., Lee S.Y., Kim E.K., Park M. J., Kim K.W. et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis, Mediators Inflamm., 2014, Vol. 2014, p. 973986.Wahdan-Alaswad R.S., Cochrane D.R., Spoelstra N.S., Howe E.N., Edgerton S.M., Anderson S.M. et al. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193bб Horm. Cancer, 2014, Vol. 5, No. 6, pp. 374–389.Wahdan-Alaswad R.S., Cochrane D.R., Spoelstra N.S., Howe E.N., Edgerton S.M., Anderson S.M. et al. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193bб Horm. Cancer, 2014, Vol. 5, No. 6, pp. 374–389.Yang Q., Zhang T., Wang C., Jiao J., Li J., Deng Y. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells, Eur. J. Pharm. Biopharm., 2014, Vol. 88, No. 3, pp. 737–745.Yang Q., Zhang T., Wang C., Jiao J., Li J., Deng Y. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells, Eur. J. Pharm. Biopharm., 2014, Vol. 88, No. 3, pp. 737–745.Damjanovic A., Matic I.Z., Ethordic M., Ethurovic M.N., Nikolic S., Roki K. et al. Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells, Pathol. Oncol. Res., 2015, Vo. 21, No. 3, pp. 605–612.Damjanovic A., Matic I.Z., Ethordic M., Ethurovic M.N., Nikolic S., Roki K. et al. Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells, Pathol. Oncol. Res., 2015, Vo. 21, No. 3, pp. 605–612.Ling S., Tian Y., Zhang H., Jia K., Feng T., Sun D. et al. Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel7402/5fluorouracil cells. Mol. Med. Rep., 2014, Vol. 10, No. 6, pp. 2891–2897.Ling S., Tian Y., Zhang H., Jia K., Feng T., Sun D. et al. Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel7402/5fluorouracil cells. Mol. Med. Rep., 2014, Vol. 10, No. 6, pp. 2891–2897.Salani B., Del R.A., Marini C., Sambuceti G., Cordera R., Maggi D. Metformin, cancer and glucose metabolism, Endocr. Relat. Cancer, 2014, Vol. 21, No. 6, pp. R461–R471.Salani B., Del R.A., Marini C., Sambuceti G., Cordera R., Maggi D. Metformin, cancer and glucose metabolism, Endocr. Relat. Cancer, 2014, Vol. 21, No. 6, pp. R461–R471.Fontaine E. Metformin and respiratory chain complex I: the last piece of the puzzle? Biochem. J., 2014, Vol. 463, No. 3, pp. e3–e5.Fontaine E. Metformin and respiratory chain complex I: the last piece of the puzzle? Biochem. J., 2014, Vol. 463, No. 3, pp. e3–e5.Troncone M., Cargnelli S.M., Villani L.A., Isfahanian N., Broadfield L.A., Zychla L. et al. Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy; translational biology and rationale for current clinical trials, Oncotarget, 2017, Apr 27.Troncone M., Cargnelli S.M., Villani L.A., Isfahanian N., Broadfield L.A., Zychla L. et al. Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy; translational biology and rationale for current clinical trials, Oncotarget, 2017, Apr 27.Marini C., Ravera S., Buschiazzo A., Bianchi G., Orengo A.M., Bruno S. et al. Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt, Sci. Rep., 2016, No. 6, 25092.Marini C., Ravera S., Buschiazzo A., Bianchi G., Orengo A.M., Bruno S. et al. Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt, Sci. Rep., 2016, No. 6, 25092.Garbati P., Ravera S., Scarfi S., Salis A., Rosano C., Poggi A. et al. Effects on Energy Metabolism of Two Guanidine Molecules, (Boc) 2-Creatine and Metformin, J. Cell Biochem., 2017.Garbati P., Ravera S., Scarfi S., Salis A., Rosano C., Poggi A. et al. Effects on Energy Metabolism of Two Guanidine Molecules, (Boc) 2-Creatine and Metformin, J. Cell Biochem., 2017.Zhao D., Long X.D., Lu T. F., Wang T., Zhang W.W., Liu Y.X. et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma, Int. J. Cancer, 2015, Vol. 136, No. 11, pp. 2556–2565.Zhao D., Long X.D., Lu T. F., Wang T., Zhang W.W., Liu Y.X. et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma, Int. J. Cancer, 2015, Vol. 136, No. 11, pp. 2556–2565.Cheng J., Huang T., Li Y., Guo Y., Zhu Y., Wang Q. et al. AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma, PLoS One, 2014, Vol. 9, No. 4, e93256.Cheng J., Huang T., Li Y., Guo Y., Zhu Y., Wang Q. et al. AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma, PLoS One, 2014, Vol. 9, No. 4, e93256.Koh S. J., Kim J.M., Kim I.K., Ko S.H., Kim J.S. Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer, J. Gastroenterol. Hepatol., 2014, Vol. 29, No. 3, pp. 502–510.Koh S. J., Kim J.M., Kim I.K., Ko S.H., Kim J.S. Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer, J. Gastroenterol. Hepatol., 2014, Vol. 29, No. 3, pp. 502–510.

The authors declare that there are no conflicts of interest present.